<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892447</url>
  </required_header>
  <id_info>
    <org_study_id>SJES001</org_study_id>
    <nct_id>NCT03892447</nct_id>
  </id_info>
  <brief_title>The Comparative Effectiveness of Alprostadil,Sodium Ferulate and Dopamine in Pediatric Acute Kidney Injury</brief_title>
  <official_title>A 52-week Multicenter, Randomized, Double-blind, Prospective Study to Evaluate Comparative Effectiveness and Safety of Alprostadil Injection,Sodium Ferulate and Dopamine Injection in Pediatric Acute Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shengjing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute kidney injury (AKI) is a pervasive clinical event in children.It has been independently&#xD;
      associated with prolonged hospital stays, risk of in-hospital death and future progression to&#xD;
      chronic kidney disease. Except for removal of nephrotoxic agents and optimization of&#xD;
      supportive care,there are still no other effective therapeutic options recommended by recent&#xD;
      guidelines. Renal ischemia is the main mechanism of AKI, the improving microcirculation&#xD;
      therapy would be the effective management to improve the outcome of AKI in children.&#xD;
&#xD;
      Dopamine is a vasodilating drug that in small doses improves renal circulation. Alprostadil&#xD;
      have been used in chronic arterial occlusion and Sodium Ferulate in ischemic cerebral&#xD;
      vascular disease,they have a similar therapeutic effect of anti-platelet aggregation and&#xD;
      vasodilation. Recent research shows that alprostadil might be associated with a significant&#xD;
      reduction in postcontrast Scr, blood urine nitrogen (BUN) and Cystatin C (CysC) level and&#xD;
      decrease the incidence of contrast-induced nephropathy.The investigators speculate that&#xD;
      Alprostadil,Sodium Ferulate and dopamine would be effective in treating AKI in children.&#xD;
&#xD;
      This is a prospective, multicenter, randomized, double-blind, 52-week study. The purpose of&#xD;
      this study is to evaluate the comparative effectiveness and safety of Alprostadil,Sodium&#xD;
      Ferulate and dopamine in improving the outcome of AKI in children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to explore the effective treatment of pediatric AKI and improve the outcome.&#xD;
      It is a 52-week multicenter, randomized, double-blind,prospective study to evaluate&#xD;
      comparative effectiveness and safety of alprostadil injection,sodium ferulate and dopamine&#xD;
      injection. This study plans to recruit 8 to 10 centers, with 300 participants randomly&#xD;
      divided into 3 groups and given respectively Alprostadil 0.2~0.3ug/kg.h,iv,1h/d,14d,Sodium&#xD;
      Ferulate2~6mg/kg.d,iv,14d,Dopamine3~5ug/kg .min,iv,3h/d,14d.Time of outcome measurement is&#xD;
      1w,2w,4w,24w,52w. Primary Outcome Measures is The change of Serum creatinin from baseline,&#xD;
      estimated glomerular filtration rate (eGFR) and urine volume in the participants after the&#xD;
      use of the study drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum creatinin</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>The change of Serum creatinin from baseline after the use of the study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>eGFR</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>The change of eGFR from baseline after the use of the study drug. eGFR (ml/min/1.73m2)=K×L/SCr. L: Height(cm), SCr: serum creatinin (umol/L),K:36.5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine volume</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>The change of urine volume from baseline after the use of the study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary markers：White Blood Cell (WBC)</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>Obtained through routine urine examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary markers：Red Blood Cell (RBC)</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>Obtained through routine urine examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary markers：Urine protein</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>Obtained through routine urine examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum urea</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>Obtained through renal function test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Cystatin</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>Obtained through renal function test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Three dimensional(3D) color ultrasound Imaging</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>Size of kidneys,Blood flow of renal arteries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stays</measure>
    <time_frame>baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Children AKI Patients</condition>
  <arm_group>
    <arm_group_label>Alprostadil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alprostadil 0.2~0.3ug/kg.h,iv,1h/d,14d; Dopamine3～5 ug/kg·min,iv,3 h/d,14d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Ferulate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium Ferulate 2~6mg/kg.d,iv,14d; Dopamine3～5 ug/kg·min,iv,3 h/d,14d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprostadil</intervention_name>
    <description>Alprostadil 0.2~0.3ug/kg.h,iv,1h/d,14d</description>
    <arm_group_label>Alprostadil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Ferulate</intervention_name>
    <description>Sodium Ferulate 2~6mg/kg.d,iv,14d</description>
    <arm_group_label>Sodium Ferulate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dopamine</intervention_name>
    <description>Dopamine3～5 ug/kg·min,iv,3 h/d,14d</description>
    <arm_group_label>Alprostadil</arm_group_label>
    <arm_group_label>Sodium Ferulate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide informed consent signed and dated by participants and/or their guardians&#xD;
&#xD;
          2. male or female, Asian.&#xD;
&#xD;
          3. Aged from 1 to 18 years.&#xD;
&#xD;
          4. Patients meet the AKI diagnosis criteria of 2012 Kidney Disease: Improving Global&#xD;
             Outcome (SKDIGO) Guideline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. prerenal or postrenal failure&#xD;
&#xD;
          2. Patients need renal replacement therapy&#xD;
&#xD;
          3. Patients with hemorrhagic disorders&#xD;
&#xD;
          4. Patients in shock&#xD;
&#xD;
          5. Patients with multiple organ failure&#xD;
&#xD;
          6. History of Alprostadil or Sodium Ferulate or dopamine sensitivity&#xD;
&#xD;
          7. Patients with heart failure&#xD;
&#xD;
          8. Patients with peptic ulcer&#xD;
&#xD;
          9. Patients with glaucoma&#xD;
&#xD;
         10. Patients with interstitial pneumonia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yubin Wu, Professor</last_name>
    <phone>18940257958</phone>
    <email>wuyb001@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shenjing Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://kdigo.org/</url>
    <description>2012 SKDIGO Guideline</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shengjing Hospital</investigator_affiliation>
    <investigator_full_name>Yubin Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>AKI</keyword>
  <keyword>Child</keyword>
  <keyword>Alprostadil</keyword>
  <keyword>Sodium Ferulate</keyword>
  <keyword>Dopamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferulic acid</mesh_term>
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Alprostadil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Dear Sir/Madam Our study receives a grant from China Ministry of Science and Technology. We cannot decide whether the data could be shared. Hope you can understand.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

